CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
1.790
-0.260 (-12.68%)
At close: Feb 21, 2025, 4:00 PM
1.710
-0.080 (-4.47%)
After-hours: Feb 21, 2025, 7:56 PM EST
CERO Employees
As of December 31, 2023, CERo Therapeutics Holdings had 9 total employees, including 8 full-time and 1 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$609,795
Market Cap
3.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
CERO News
- 16 days ago - CERo Therapeutics Holdings, Inc. Highlights Progress - GlobeNewsWire
- 17 days ago - CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewsWire
- 3 months ago - CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia - GlobeNewsWire
- 3 months ago - CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity - GlobeNewsWire
- 4 months ago - CERo Therapeutics, Inc. Provides Corporate Update - GlobeNewsWire
- 5 months ago - CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer - GlobeNewsWire
- 5 months ago - Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump - Benzinga